ID: ALA297327

Max Phase: Preclinical

Molecular Formula: C32H47N3O5

Molecular Weight: 553.74

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)(C)OC(=O)N[C@@](C)(Cc1ccccc1)C(=O)N[C@H](Cc1ccccc1)C(=O)NCCCCCCCCO

Standard InChI:  InChI=1S/C32H47N3O5/c1-31(2,3)40-30(39)35-32(4,24-26-19-13-10-14-20-26)29(38)34-27(23-25-17-11-9-12-18-25)28(37)33-21-15-7-5-6-8-16-22-36/h9-14,17-20,27,36H,5-8,15-16,21-24H2,1-4H3,(H,33,37)(H,34,38)(H,35,39)/t27-,32+/m1/s1

Standard InChI Key:  ZYOSMLUSASXSFL-ZUKKLESISA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 553.74

Molecular Weight (Monoisotopic): 553.3516

AlogP: 4.69

#Rotatable Bonds: 16

Polar Surface Area: 116.76

Molecular Species: NEUTRAL

HBA: 5

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 8

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 12.60

CX Basic pKa:

CX LogP: 5.20

CX LogD: 5.20

Aromatic Rings: 2

Heavy Atoms: 40

QED Weighted: 0.23

Np Likeness Score: -0.24

References

1. Boden P, Eden J, Hodgson J, Horwell D, Howson W, Hughes J, McKnight A, Meecham K, Pritchard M, Raphy J, Ratcliffe G, Suman-Chauhan N, Woodruff G.  (1994)  The rational development of small molecule tachykinin NK3 receptor selective antagonists - the utilisation of a dipeptide chemical library in drug design,  4  (14): [10.1016/S0960-894X(00)80360-1]

Source

Source(1):

• Scientific Literature